National Chemical Laboratories’ OTC topical drugs were adulterated after FDA found manufacturing quality violations, including untested BZK and weak quality oversight.
What happened
FDA inspected National Chemical Laboratories’ drug manufacturing facility in Philadelphia from May 22 to 26, 2023. FDA found that the firm could not show component testing for benzalkonium chloride (BZK), including identity, and relied on supplier test reports (certificates of analysis) without establishing their reliability. FDA also found quality-unit oversight failures, inadequate stability and cleaning programs, and repeated failures from a 2021 inspection; the firm said it ceased drug production.
What FDA found
The firm did not test benzalkonium chloride lots for identity and relied on supplier certificates of analysis without establishing the supplier’s test reliability.
21 CFR 211.84(d)(2)The quality control unit did not adequately oversee manufacturing to ensure drug products met identity, strength, quality, and purity requirements.
21 CFR 211.22The firm lacked an adequate ongoing stability program for its drug products.
21 CFR 211.166(a)The firm did not have adequate written procedures for out-of-specification results, deviations, equipment cleaning, process validation, and pest control.
21 CFR 211.22(d)The firm did not adequately validate or have approved written procedures for cleaning and maintaining non-dedicated manufacturing equipment.
21 CFR 211.67(b)
What FDA wants
FDA asks the company to respond in writing within 15 working days with corrections and preventive actions, clarify whether it will resume drug manufacturing, notify FDA before resuming, and engage a qualified consultant before resuming operations.
Who should pay attention
- brands or distributors selling OTC hand sanitizers made by this firm
- contract manufacturers and suppliers of BZK or other drug components
- companies relying on supplier certificates of analysis without identity testing
This is a summary. Read the original letter on fda.gov.